REV-400

N/A

Report date: 2026/03/19 17:01:29

Base Information

Drug NameREV-400

Drug Alias NameREV-400

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionProgrammed death-ligand 1 blockersT cell surface glycoprotein CD3 modulatorsAnti-Epidermal growth factor receptor erbB1

TargetsProgrammed death-ligand 1T cell surface glycoprotein CD3Epidermal growth factor receptor erbB1

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesRevitope Oncology Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A